What are the Contents of the New Drug Preclinical Research?

Preclinical research content of new drugs:

Literature research (drug name and naming basis, title and basis)

Pharmaceutical research (raw material drug technology research, preparation prescription and technology research, etc.)

Pharmacology and toxicology research (general pharmacology experiment, main pharmacodynamic experiment, acute toxicity experiment, long-term toxicity experiment, etc.)

The stage and purpose of the clinical research of the new drug:

Phase I clinical trial (safety):

preliminary clinical pharmacology and human safety evaluation test. Observe the human body’s tolerance and pharmacokinetics of new drugs to provide a basis for formulating dosing regimens.

Phase II clinical trial (effectiveness):

the preliminary evaluation stage of the therapeutic effect. Its purpose is to preliminarily evaluate the therapeutic effect and safety of the drug on patients with target indications, and also to provide a basis for the design of phase III clinical trials and the determination of the dosage regimen.
The research design at this stage can adopt various forms according to specific research purposes, including randomized blinded controlled clinical trials.

Phase III clinical trial:

the stage of confirmation of the therapeutic effect. Its purpose is to further verify the therapeutic effect and safety of the drug on patients with target indications, evaluate the relationship between benefits and risks, and ultimately provide a sufficient basis for the review of drug registration applications. The test should generally be a randomized blinded controlled trial with sufficient sample size.

Phase IV clinical trials:

the application research phase of the new drug after it is marketed. Its purpose is to investigate the efficacy and adverse reactions of the drug under widely used conditions, to evaluate the relationship between benefits and risks in general or special populations, and to improve the dosage at the first level.
Bioequivalence test refers to the method of bioavailability research, using pharmacokinetic parameters as an indicator to compare the same or different dosage forms of the same drug, under the same test conditions, the absorption degree and speed of its active ingredients There are no statistical differences in human trials.

Contact Us:

Email : marketing@medicilon.com

Tel : +44 1223 981 792 (Europe)

+82 (0)70-8269-5849 (South Korea)

08044216898 (Japan)

+86 021 58591500 (China)

Website: https://www.medicilon.com

Preclinical Drug Development Process

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

Shanghai Medicilon Inc.

搜索此博客